Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients.

摘要: Between April, 1992 and December, 1995, forty consecutive patients with a cerebral malignant glioma (WHO Grade III IV) were enrolled in trial consisting surgery post-operative administration of radiotherapy (4500-6000 cGy), carboplatin (CBDCA; dose 450-600 mg/m2), oral tamoxifen (TAM; at doses 40, 80 or 120 mg/day). Two the TAM group died postoperative period from pulmonary embolism myocardial infarction, respectively. The (all dosages combined) had median survival time 13 months diagnosis. 12-month 24-month rates 52% 32%, relapse-free was 7 months. Patients treated higher (80-120 mg/day) demonstrated longer rate (13 both) result (58% 76%, respectively). who assumed for than 3 (group +3) have (16 months) better results (62% 40%, Moreover, 10 (versus 6 -3; p = 0.0038). However, it is not possible to exclude that +3 slower growing stable tumor well enough assume period. observed TAM-group been compared those 40 matched controls surgery, CBDCA. These 9 (p 0.04) 30% 0%, 4 0.0014). data suggest potential role combinational TAM-CBDCA therapy treatment gliomas; further clinical phase trials, especially are warranted.